# A Study Evaluating the Effectiveness of PEA Compared to Placebo for Reducing Pain Severity and Duration of Migraines.

> **NCT05046522** · PHASE3 · COMPLETED · sponsor: **RDC Clinical Pty Ltd** · enrollment: 80 (actual)

## Conditions studied

- Migraine

## Interventions

- **DRUG:** Palmitoylethanolamide sold as Levagen +
- **DRUG:** Placebo comparator - maltodextrin and microcrystalline cellulose mix

## Key facts

- **NCT ID:** NCT05046522
- **Lead sponsor:** RDC Clinical Pty Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-09-01
- **Primary completion:** 2023-03-09
- **Final completion:** 2023-03-09
- **Target enrollment:** 80 (ACTUAL)
- **Last updated:** 2023-10-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05046522

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05046522, "A Study Evaluating the Effectiveness of PEA Compared to Placebo for Reducing Pain Severity and Duration of Migraines.". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05046522. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*